Literature DB >> 24493670

Tracing the development of acute myeloid leukemia in CBL syndrome.

Heiko Becker1, Kenichi Yoshida, Nadja Blagitko-Dorfs, Rainer Claus, Milena Pantic, Mahmoud Abdelkarim, Christoph Niemöller, Christine Greil, Björn Hackanson, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Konstanze Döhner, Susanne Schnittger, Philipp Henneke, Charlotte M Niemeyer, Christian Flotho, Dietmar Pfeifer, Seishi Ogawa, Michael Lübbert.   

Abstract

We describe the development of acute myeloid leukemia (AML) in an adult with CBL syndrome caused by a heterozygous de novo germline mutation in CBL codon D390. In the AML bone marrow, the mutated CBL allele was homozygous after copy number-neutral loss-of-heterozygosity and amplified through a chromosomal gain; moreover, an inv(16)(p13q22) and, as assessed by whole-exome sequencing, 12 gene mutations (eg, in CAND1, NID2, PTPRT, DOCK6) were additionally acquired. During complete remission of the AML, in the presence of normal blood counts, the hematopoiesis stably maintained the homozygous CBL mutation, which is reminiscent of the situation in children with CBL syndrome and transient juvenile myelomonocytic leukemia. No additional mutations were identified by whole-exome sequencing in granulocytes during complete remission. The study highlights the development of AML in an adult with CBL syndrome and, more generally, in genetically aberrant but clinically inconspicuous hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24493670     DOI: 10.1182/blood-2013-10-533844

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Identification of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia.

Authors:  Heiko Becker; Gabriele Greve; Keisuke Kataoka; Jan-Philipp Mallm; Jesús Duque-Afonso; Tobias Ma; Christoph Niemöller; Milena Pantic; Justus Duyster; Michael L Cleary; Julia Schüler; Karsten Rippe; Seishi Ogawa; Michael Lübbert
Journal:  Blood Adv       Date:  2019-03-12

2.  Acquired expression of CblQ367P in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia.

Authors:  Yuichiro Nakata; Takeshi Ueda; Akiko Nagamachi; Norimasa Yamasaki; Ken-Ichiro Ikeda; Yasuyuki Sera; Keiyo Takubo; Akinori Kanai; Hideaki Oda; Masashi Sanada; Seishi Ogawa; Kohichiro Tsuji; Yasuhiro Ebihara; Linda Wolff; Zen-Ichiro Honda; Toshio Suda; Toshiya Inaba; Hiroaki Honda
Journal:  Blood       Date:  2017-02-16       Impact factor: 22.113

3.  UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.

Authors:  S Goyama; J Schibler; A Gasilina; M Shrestha; S Lin; K A Link; J Chen; S P Whitman; C D Bloomfield; D Nicolet; S A Assi; A Ptasinska; O Heidenreich; C Bonifer; T Kitamura; N N Nassar; J C Mulloy
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

Review 4.  Receptor-type protein tyrosine phosphatases in cancer.

Authors:  Yu Du; Jennifer R Grandis
Journal:  Chin J Cancer       Date:  2014-10-17

Review 5.  Role of CBL Mutations in Cancer and Non-Malignant Phenotype.

Authors:  Davide Leardini; Daria Messelodi; Edoardo Muratore; Francesco Baccelli; Salvatore N Bertuccio; Laura Anselmi; Andrea Pession; Riccardo Masetti
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

6.  Casitas B-lineage lymphoma Gene Mutation Ocular Phenotype.

Authors:  Christine Fardeau; Munirah Alafaleq; Marie-Adélaïde Ferchaud; Miguel Hié; Caroline Besnard; Sonia Meynier; Frédéric Rieux-Laucat; Damien Roos-Weil; Fleur Cohen; Isabelle Meunier
Journal:  Int J Mol Sci       Date:  2022-07-17       Impact factor: 6.208

7.  PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients.

Authors:  Hung-Chih Hsu; Nina Lapke; Shu-Jen Chen; Yen-Jung Lu; Ren-Shiang Jhou; Chien-Yuh Yeh; Wen-Sy Tsai; Hsin-Yuan Hung; Jason Chia-Hsun Hsieh; Tsai-Sheng Yang; Tan Kien Thiam; Jeng-Fu You
Journal:  Cancers (Basel)       Date:  2018-09-06       Impact factor: 6.639

8.  Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition.

Authors:  Cristina Andrés-Zayas; Julia Suárez-González; Gabriela Rodríguez-Macías; Nieves Dorado; Santiago Osorio; Patricia Font; Diego Carbonell; María Chicano; Paula Muñiz; Mariana Bastos; Mi Kwon; José Luis Díez-Martín; Ismael Buño; Carolina Martínez-Laperche
Journal:  Mol Oncol       Date:  2021-07-16       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.